Prophylactic Antiepileptic Treatment in Tuberous Sclerosis

Prerna Choudhury, Robert Spaull, Sam Amin, Andrew A Mallick, Jayesh S Patel, Finbar O'Callaghan, Andrew L Lux*

*Corresponding author for this work

Research output: Contribution to journalLetter (Academic Journal)peer-review

Abstract

Jóźwiak et al. suggest that their study, “…provides evidence that preventive antiepileptic treatment in infants with tuberous sclerosis complex improves long-term epilepsy control and cognitive outcome at school age.” The study is problematic, however, because it compares two groups that have been ascertained in entirely different ways: the “Standard” group after presentation with tuberous sclerosis complex and usually epilepsy and the “Preventive” group with suspected or proven tuberous sclerosis complex but without epilepsy.
Original languageEnglish
Pages (from-to)100-101
Number of pages2
JournalPediatric Neurology
Volume110
Early online date5 Apr 2020
DOIs
Publication statusPublished - 1 Sep 2020

Bibliographical note

Acceptance date is provisional and based on date of publication.

Keywords

  • tuberous sclerosis complex
  • vigabatrin
  • antiepileptic drug treatment

Fingerprint Dive into the research topics of 'Prophylactic Antiepileptic Treatment in Tuberous Sclerosis'. Together they form a unique fingerprint.

Cite this